The Scarlet RoAD study (a Phase III trial), researching the anti-amyloid drug Gantenerumab for the possible treatment of prodromal (pre-dementia) Alzheimer’s Disease, has been abandoned following disappointing results.
Gantenerumab-related research (in a different Phase III investigation) is still underway for the possible treatment of Alzheimer’s Disease at a later stage. Roche remains committed to drugs development for dementia generally.
Roche (RHHBY) suffers a double blow as breast cancer, Alzheimer’s drug studies fail; pulls plug on ALZ’s drug development. [Online, USA]: Biospace Inc., December 19th 2014.